A pharmacoeconomic comparison of atorvastatin vs rosuvastatin in treatment of acute coronary syndrome in tertiary care hospital

Abstract

Background: Pharmacoeconomics is a scientific discipline that evaluates the value of one pharmaceutical drug or therapy compared to another. It analyses the costs and effects of pharmaceutical products. The treatment and prevention of acute coronary syndrome (ACS) incur high costs, and the growing demand for clinical interventions further strains healthcare resources. Identifying cost-effective therapeutic options is vital for optimising resource utilisation.Objective: This study aimed to identify the most cost-effective drug combination for ACS treatment and reduce patients’ financial burden.Methodology: A prospective observational study was conducted over two months at Madhu Hospital, Adoni, involving 80 patients aged 18–80 years diagnosed with ACS. Participants were randomly assigned into two groups: Group A received atorvastatin (40 mg) and Group B received rosuvastatin (20 mg), both administered orally once daily. Lipid profiles were monitored monthly.Results: A statistically significant reduction in abnormal lipid profiles was observed in both groups. However, atorvastatin demonstrated greater cost-effectiveness compared to rosuvastatin. Monthly follow-ups confirmed these findings.Conclusion: This pharmacoeconomic analysis concluded that atorvastatin is a more cost-effective option than rosuvastatin for treating ACS.